Literature DB >> 3159443

CALLA-positive myeloma: an aggressive subtype with poor survival.

B G Durie, T M Grogan.   

Abstract

Detailed immunotyping was carried out on 21 direct myeloma bone marrow aspirates and eight human myeloma cell lines. Four previously untreated common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma patients were identified and six of eight cell lines (75%) were also positive. CALLA positivity, as part of an immature B phenotype, was found to correlate with very aggressive clinical disease: median survival six months v 56 months for the CALLA-negative group.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3159443

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

Authors:  R Leo; M Boeker; D Peest; R Hein; R Bartl; J E Gessner; J Selbach; G Wacker; H Deicher
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

2.  CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

Authors:  M Zandecki; T Facon; F Bernardi; V Izydorczyk; L Dupond; M François; R Reade; T Iaru; F Bauters; A Cosson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

3.  An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.

Authors:  N Jackson; N R Ling; J Ball; E Bromidge; P D Nathan; I M Franklin
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

Review 4.  Current drug therapy for multiple myeloma.

Authors:  Y W Huang; A Hamilton; O J Arnuk; P Chaftari; R Chemaly
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

5.  Expression of the neural cell adhesion molecule (CD56) by human myeloma cells.

Authors:  J Drach; C Gattringer; H Huber
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

6.  Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).

Authors:  D M Menke; H P Horny; H Griesser; E J Atkinson; E Kaiserling; R A Kyle
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

7.  Different reactivity of monoclonal antibodies against common acute lymphoblastic leukaemia antigen (CD10).

Authors:  S Haralambidou; J V Melo; D Catovsky
Journal:  J Clin Pathol       Date:  1987-05       Impact factor: 3.411

8.  Establishment of five human myeloma cell lines.

Authors:  M Namba; T Ohtsuki; M Mori; A Togawa; H Wada; T Sugihara; Y Yawata; T Kimoto
Journal:  In Vitro Cell Dev Biol       Date:  1989-08

9.  Clinical features of common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma: report of four cases.

Authors:  J Tamura; H Kurabayashi; M Sawamura; H Murakami; E Nogiwa; S Shinonome; S Miyawaki; K Kubota; S Sato; M Omine
Journal:  Blut       Date:  1989-05

10.  Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.

Authors:  L Bergui; M Schena; G Gaidano; M Riva; F Caligaris-Cappio
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.